Update on medical therapy for male LUTS

Sidney B. Radomski, MD, FRCSC
Professor of Surgery (Urology), University of Toronto, Toronto Western Hospital, Toronto, ON

Abstract

The medical management of lower urinary tract symptoms (LUTS) is aimed at addressing voiding and storage symptoms in patients with benign prostate hyperplasia (BPH) symptoms with or without an overactive bladder (OAB). Current available options for BPH include alpha-blockers, 5-alpha reductase inhibitors and phosphodiesterase type 5 inhibitors. For OAB, options include antimuscarinics, with or without an alpha-blocker, the beta-3-adrenergic agonist mirabegron and the synthetic diuretic desmopressin. With the availability of numerous options and combinations available for the treatment of LUTS, individual patient assessment is the key to optimal symptom control and management of adverse effects.

Introduction

Lower urinary tract symptoms (LUTS) include both storage and voiding symptoms. Storage symptoms, formerly known as irritative symptoms, include frequency, urgency, nocturia, and urgency incontinence. Voiding symptoms, formerly known as obstructive symptoms, include symptoms involving a weak urinary stream, hesitancy, intermittency, straining to void, postmicturition dribbling and feelings of incomplete emptying. The prevalence and severity of LUTS increases with age and often has a significant negative impact on quality of life.

Benign prostatic hyperplasia

The LUTS associated with benign prostatic hyperplasia (BPH) include both storage/irritative symptoms, such as frequency, urgency, nocturia, and urgency incontinence. Voiding symptoms, formerly known as obstructive symptoms, include symptoms involving a weak urinary stream, hesitancy, intermittency, straining to void (Table 1). The treatment of LUTS is guided by the severity of the symptoms, the degree of bother and patient preference (Fig. 1). The mainstay of medical treatments includes alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs), or a combination of the two. But with the availability of phosphodiesterase type 5 (PDE5) inhibitors and the use of drugs to treat overactive bladder (OAB) there are increased options and combinations to treat patients.

Alpha-blockers

For patients with moderate to severe LUTS secondary to BPH, alpha-blockers such as alfuzosin, doxazosin, tamsulosin and terazosin are appropriate treatment options. For OAB, options include antimuscarinics, with or without an alpha-blocker, the beta-3-adrenergic agonist mirabegron and the synthetic diuretic desmopressin. With the availability of numerous options and combinations available for the treatment of LUTS, individual patient assessment is the key to optimal symptom control and management of adverse effects.

5-ARIs

The 5-ARIs dutasteride and finasteride are effective treatments for patients with demonstrable prostatic enlargement to prevent progression of LUTS. In addition to improving symptoms, 5-ARIs have been shown to alter the natural history of BPH by reducing the risk of acute urinary retention (AUR) and the need for surgical intervention through a reduction in prostate volume.

Patients with LUTS associated with prostatic enlargement may be offered a combination of an alpha-blocker and a 5-ARI, which has been shown to delay symptomatic disease progression, AUR and prostate surgery compared with either therapy alone. If combination therapy is successful, patients may be given the option of discontinuing the alpha-blocker after 6 to 9 months of therapy, and the alpha-blocker restarted if symptoms recur.

PDE5 Inhibitors

The PDE5 inhibitors, such as sildenafil, vardenafil and tadalafil, have shown improvement in symptoms and quality-of-life in men with LUTS, either with or without ED. A recent meta-analysis
Medical therapy for male LUTS

Demonstrated a 2.8-point decrease in International Prostate Symptom Score (I-PSS) and a 5.5-point increase in the International Index of Erectile Function (IIEF), with no effect on peak urinary flow. The same meta-analysis showed that a combination of PDE5 inhibitor and alpha-blocker improved IIEF by 3.6 points and lowered I-PSS by 1.8 points, with an increase in peak urinary flow of 1.5 mL/s compared with alpha-blocker alone. The CUA guidelines do not currently recommend the use of PDE5 inhibitors for men with symptomatic BPH-related LUTS. However, when the guidelines are updated they will likely be included in the algorithm.

OAB

OAB is a common voiding dysfunction problem characterized by urinary frequency, urgency and at times urgency incontinence. In men, symptoms of OAB may be mistaken for BPH, and many men can suffer from both OAB and BPH. Over the past number of years there has been has been increased use of anticholinergic medication along with the typical use of alpha-blockers and 5ARIs to safely treat LUTS in men with BPH. The long standing concerns in the past that anticholinergic drugs were contraindicated due to the risk of retention in these men have been dispelled in numerous studies.

Antimuscarinics

Antimuscarinics, with or without an alpha-blocker, may be effective for the treatment of the storage symptoms of OAB in some men. In patients with symptoms of OAB, the addition of an antimuscarinic agent such as solifenacin, tamsulosin, or oxybutynin following initial treatment with an alpha1-selective alpha-blocker has been shown to improve persistent storage symptoms to a greater degree than the alpha-blocker alone. In men with predominant storage LUTS, antimuscarinic monotherapy is well tolerated and improves symptoms such as bedwetting and urgency urinary incontinence.

A concern with the use of antimuscarinics in men with BPH is the risk of acute urinary retention (AUR). AUR has been reported to occur at a rate of less than 1% in clinical trials, and up to 2.5% in real life practice. The risk of developing AUR is highest during the first 90 days of treatment.

Mirabegron

Mirabegron is a beta-3 agonist approved in the United States and Canada for the treatment of OAB. By activating beta-3 receptors in the bladder, mirabegron causes relaxation of the smooth muscle, which results in increased storage capacity of the bladder and a prolonged interval between voids. In a placebo-controlled trial of 200 men with symptoms of LUTS and bladder outlet obstruction, 12 weeks of treatment with mirabegron did not adversely affect voiding parameters on urodynamics, including maximum urinary flow and detrusor pressure at maximum urinary flow, when compared with placebo.

Desmopressin

Desmopressin acetate is a synthetic form of the anti-diuretic hormone vasopressin, and has been used for the treatment of nocturia and nocturnal enuresis in children and adults. Desmopressin was evaluated in a randomized, double-blind
trial of 385 men with nocturia, defined as two or more nocturnal voids. Primary end points were changes from baseline in mean number of nocturnal voids and proportions of patients achieving a minimum 33% reduction from baseline in nocturnal voids. A significant reduction in nocturnal voids (0.37 and 0.41) was seen by one week—a response that was sustained through the three months of the trial. Desmopressin also significantly increased the odds of having a 33% reduction in nocturnal voids, and resulted in significant increases in health-related quality of life and sleep. Hence, desmopressin may be an additional option for men with significant nocturia refractory to other available medication. In clinical practice, the use of desmopressin for OAB may have a role in patients with primary nocturnal enuresis who do not have underlying electrolyte disturbance or risk factors for hyponatremia. Older patients in particular are at risk of precipitating fluid retention, hyponatremia, and worsening underlying cardiac failure.

Conclusions

With the availability of numerous options and combinations for the treatment of LUTS in men, patient selection is the key to optimal symptom control and management of adverse effects. Patients undergoing these treatments require close initial follow-up to monitor side effects and to assess symptom improvement.

Competing interests: Dr. Radomski is an ongoing paid consultant with Allergan, Astellas, Eli Lilly, Men's Labs, Pfizer, and Watson. He has also received speaker fees, educational grants, and/or travel assistance from Allergan, Astellas, Eli Lilly, and Pfizer within the past 2 years.

References


Correspondence: Dr. Sidney B. Radomski, Toronto Western Hospital, Main Pavilion, 8th Floor Rm. 304, 399 Bathurst St., Toronto, ON M5T 2S8; sidney.radomski@uhn.ca